04/07/2020
11/05/2020
DGHO guideline on coronavirus infection
in patients with blood and cancer diseases
**** updated on 05/11/2020 ****
The German Society for Hematology and Medical Oncology (DGHO) updated its guideline for coronavirus infection (COVID-19) in patients with blood and cancer diseases on May 11, 2020. In its guideline, the DGHO explains what SARS-CoV-2 exactly means, names the risk factors and gives advice on prevention and therapy, among other things. She deals with aplastic anemia under point 6.2.9, PNH under point 6.2.56. For further information on COVID-19, see also the information provided by Dr. Höchsmann made recommendations as well as our blog post .
12/04/2020
AA & PNH eV on Facebook
Our association Aplastic Anemia & PNH eV, AA & PNH eV for short, now has its own page on Facebook ! There we present the association and its history. We also point out events such as group meetings and patient days as well as information on the diseases and current topics.
WEITER
12/03/2020
Information on the COVID-19 pandemic for AA and PNH patients
UPDATE - the letter has been updated:
Letter of recommendation on Corona at AA and PNH as of March 25, 2020 (2 MB)
Miss Dr. Höchsmann from the center in Ulm, which specialises in AA and PNH, has put together information and assistance in dealing with the COVID-19 pandemic. Please follow the instructions and stay as healthy as possible!
Note: The websites listed in the letter are not linked, they follow here:
WEITER
08/03/2020
DLH member annual meeting 2020
On 07. The annual general meeting of members (MJHV) of our umbrella association, the German Leukaemia & Lymphoma Aid eV (DLH) took place in Königswinter. Since the spread of the SARS-CoV-2 virus only affected a manageable number of people and the district health department had not a single case, the event could be carried out as planned.
The first day was dedicated to the advanced training of the group leaders present. 4 workshops were offered:
29/02/2020
The “corona virus”
COVID-19 or Corona virus SARS-CoV-2 is currently causing excitement or worry in many people. This is mainly due to the uncertainty that results from the novelty and the lack of experience. For the vast majority (approx. 80%) of those infected, the infection appears to be harmless. People who are older or have previous illnesses are currently considered to be particularly at risk of complications. The following information can help: WEITER
07/02/2020
Ravulizumab (Ultomiris®) with no added benefit
The Federal Joint Committee (G-BA) has certified that the second C5 complement inhibitor ravulizumab (Ultomiris®) approved against paroxysmal nocturnal hemoglobinuria (PNH) has no additional benefit compared to the appropriate comparator therapy (previous standard) eculizumab (Soliris®). This resulted in the benefit assessment procedure according to Section 35a SGB V, which was completed on February 6, 2020. WEITER
03/01/2020
Survey on working conditions
The University of Cologne - Chair for Work and Vocational Rehabilitation - would like to find out in an anonymous online survey what the working conditions of people with health impairments are like. The aim is to use the information obtained "at first hand" to help improve their working conditions in the long term. Anyone over the age of 18 who is currentlyWEITER
23/12/2019
Big donation from the JAV of the BVG
Donation handover at the JAV of the BVG
08/12/2019